Fluvoxamine for COVID-19

philipn authored on Jan. 18, 2021, 7:43 p.m.

Review changes View this version of the page

You can also use the and keys

~~Deletions are marked like this~~	Additions are marked like this
The skeletal formula of fluvoxamine. Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) which is being trialed for possible therapeutic use in COVID-19. Fluvoxamine showed promise in a randomized, placebo-controlled trial of 152 COVID-19 positive outpatients. In a paper published in November, 2020 in the Journal of the American Medical Association: Clinical deterioration occurred in 0 of 80 patients in the fluvoxamine group and in 6 of 72 patients in the placebo group (absolute difference, 8.7% [95% CI, 1.8%-16.4%] from survival analysis; log-rank P = .009). The fluvoxamine group had 1 serious adverse event and 11 other adverse events, whereas the placebo group had 6 serious adverse events and 12 other adverse events. -JAMA Fluoxetine has also shown anti-SARS-CoV-2 activity in vitro in Vero and Calu-3 cells. Mechanism of possible benefit? Sigma-1 receptor Mechanisms of potential benefit in COVID-19 may include sigma-1 receptor agonism. See "Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor" and "Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis". As SSRI An observational study of 7,345 hospitalized COVID-19 patients hinted at possible benefit of prior SSRI usage. As an anti-viral In an October, 2020 preprint, fluoxetine showed in vitro anti-SARS-CoV-2 activity in Vero and Calu-3 cells. News coverage Wired - How a Medication for OCD Ended Up in a Covid-19 Trial See also COVID-19 therapeutics	The skeletal formula of fluvoxamine. Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) which is being trialed for possible therapeutic use in COVID-19. Fluvoxamine showed promise in a randomized, placebo-controlled trial of 152 COVID-19 positive outpatients. In a paper published in November, 2020 in the Journal of the American Medical Association: Clinical deterioration occurred in 0 of 80 patients in the fluvoxamine group and in 6 of 72 patients in the placebo group (absolute difference, 8.7% [95% CI, 1.8%-16.4%] from survival analysis; log-rank P = .009). The fluvoxamine group had 1 serious adverse event and 11 other adverse events, whereas the placebo group had 6 serious adverse events and 12 other adverse events. -JAMA Fluoxetine has also shown anti-SARS-CoV-2 activity in vitro in Vero and Calu-3 cells. Mechanism of possible benefit? Sigma-1 receptor Mechanisms of potential benefit in COVID-19 may include sigma-1 receptor agonism. See "Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor" and "Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis". "Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor" As SSRI An observational study of 7,345 hospitalized COVID-19 patients hinted at possible benefit of prior SSRI usage. As an anti-viral In an October, 2020 preprint, fluoxetine showed in vitro anti-SARS-CoV-2 activity in Vero and Calu-3 cells. News coverage Wired - How a Medication for OCD Ended Up in a Covid-19 Trial See also COVID-19 therapeutics

~~Deletions are marked like this~~

Additions are marked like this

Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) which is being trialed for possible therapeutic use in COVID-19.

Fluvoxamine showed promise in a randomized, placebo-controlled trial of 152 COVID-19 positive outpatients. In a paper published in November, 2020 in the Journal of the American Medical Association:

Clinical deterioration occurred in 0 of 80 patients in the fluvoxamine group and in 6 of 72 patients in the placebo group (absolute difference, 8.7% [95% CI, 1.8%-16.4%] from survival analysis; log-rank P = .009). The fluvoxamine group had 1 serious adverse event and 11 other adverse events, whereas the placebo group had 6 serious adverse events and 12 other adverse events. -JAMA

Fluoxetine has also shown anti-SARS-CoV-2 activity in vitro in Vero and Calu-3 cells.

Mechanism of possible benefit?

Clinical deterioration occurred in 0 of 80 patients in the fluvoxamine group and in 6 of 72 patients in the placebo group (absolute difference, 8.7% [95% CI, 1.8%-16.4%] from survival analysis; log-rank P = .009). The fluvoxamine group had 1 serious adverse event and 11 other adverse events, whereas the placebo group had 6 serious adverse events and 12 other adverse events. -JAMA

Fluoxetine has also shown anti-SARS-CoV-2 activity in vitro in Vero and Calu-3 cells.